Unscripted the AMCP Podcast: HER2-Positive Biliary Tract Cancer

HER2-Positive Biliary Tract Cancer: Biomarkers, Targeted Therapy, and Managed Care Access On this episode, Jeffrey Dunn, PharmD, MBA, President and CEO of Cooperative Benefits Group, discusses the rapidly evolving treatment landscape for HER2-positive biliary tract cancer (BTC) and its implications for managed care. The discussion covers the importance of biomarker testing and molecular profiling in guiding targeted therapy, key NCCN guideline considerations across lines of treatment, and the clinical and economic impact of timely access to HER2-directed therapies. We also discuss payer-provider collaboration strategies to improve testing, coverage alignment, and patient access in this rare and aggressive form of cancer. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen/